When patients have GI bleeding while taking P2Y 12 inhibitors, such as clopidogrel, ticagrelor (Brilinta), and prasugrel (Effient), evidence is less clear
1 percent) among patients who received clopidogrel Three patients in the clopidogrel group had severe bleeding complications not related to the GI tract, including two intra-ventricular hemorrhages, one of which was
The expected rate of bleeding in the clopidogrel
Lower GI
Various factors are to be considered while choosing antiplatelet agents to prevent the risk of bleed and
In the CURE study (n=12,562), the incidence of fatal bleeding (0
1% of those on the drug)
The expected rate of bleeding in the clopidogrel group is 5%, based on the balance of existing studies
Methods: Using the National Health Insurance Research Database of Taiwan, 3238 clopidogrel
Aspirin and Plavix (clopidogrel) are drugs that prevent blood clots to reduce the risk of heart attacks and strokes, or subsequent heart attacks and strokes
The risk of bleeding varies with the type of anticoagulant agent used
Gastrointestinal bleeding, particularly upper gastrointestinal bleed (UGIB), is one of the most common serious bleeding adverse effects of antiplatelet therapy, which has led to the concurrent prescription of proton pump inhibitors (PPIs)
5
This article focuses on bleeding isolated to the colon and rectum
Compared to clopidogrel, ticagrelor significantly increased spontaneous bleeds, major bleeds, major plus minor bleeds, and major plus minor plus minimal bleeds
In a retrospective analysis, the frequency of GI bleeding in a high-risk population with prior peptic ulcer disease was
For all other patients, intravenous fluids as needed for resuscitation and red cell transfusion at a hemoglobin
A serious complication of dual antiplatelet therapy is bleeding, most of which arise from the gastrointestinal (GI) tract